摘要
目的探讨普伐他汀抑制经皮冠状动脉介入治疗后细胞外基质降解及对再狭窄的预防作用。方法62例行经皮冠状动脉介入术(percutaneouscoronaryintervention,PCI)的患者分为对照组(30例)和普伐他汀组(32例),普伐他汀用量为10mg/d,测定2组PCI前(用药前),治疗7、21dMMP-1、MMP-9水平变化。随访术后6个月再狭窄发生情况。结果所有PCI术后血流均达到TIMI3级,残余狭窄20%以下,无严重并发症发生。①PCI后应用普伐他汀可明显降低MMP-1、MMP-9水平(P<0.01)。②到随访终点,普伐他汀组有1例患者,对照组有8例患者复发心绞痛(P<0.05);所有患者术后半年进行冠状动脉造影复查,普伐他汀组有1例患者,对照组有6例患者出现再狭窄(P<0.05);两组之间,冠脉内径下降幅度差异有显著性(P<0.05)。无1例发生急性心肌梗死或需冠状动脉搭桥术。结论在PCI术后患者中,早期应用普伐他汀治疗,可减少基质成分的降解,预防再狭窄的发生。
Objective To investigate the influence （MMP-1）, MMP-9 and its role in prevention of restenosis 62 patients after percutaneous coronary intervention （PCI） of pravastatin on serum matrix metalloproteinases-1 following coronary intervention. Methods Totally were randomly assigned to receive 10 mg/d pravastatin in 24-48 h after PCI for 6 months （ n = 32） or no therapy （ n = 30） as control. The blood samples of all patients were examined at admission and 7, 21 d after administration of pravastatin. All patients received followup and coronary checking within 6 months. Results TIMI 3 flow was achieved in all eases and residual stenosis was less than 20%. No severe complications were found. ①The use of pravastatin after PCI could signifi cantly reduce serum levels of MMP-1 and MMP-9 as compared with control group （P 〈 0. 01 ）. ②At the end of 6-month follow-up, 1 case in pravastatin group and 8 case in control group experienced recurrent angina. All patients received coronary rechecking, of which only 1 case in pravastatin group but 6 in control group were found to be restenosis. There were significant differences in decreasing amplitude of minimal lumen diameter between two groups. No one occurred acute myocardial infarction or needed bypass operation of coronary artery during follow-up. Conclusion Pravastatin decreased breakdown of matrix collagen and could achieve low restenosis rate after percutaneous coronary intervention.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2006年第20期2096-2098,共3页
Journal of Third Military Medical University
关键词
PCI
普伐他汀
冠状动脉疾病
percutaneous coronary intervention
pravastatin
coronary disease
